Skip to main content
Premium Trial:

Request an Annual Quote

ACT Genomics Acquires MC Diagnostics

NEW YORK – Asian molecular diagnostic firm ACT Genomics announced on Tuesday that it has completed its acquisition of MC Diagnostics.

Financial terms of the deal were undisclosed.

The companies plan to develop fusion gene chips on MC Diagnostics' automated low density array platform, known as ALDAS, that can be performed at the point of care, ACT said in a statement. The first gene chip, called the ACTSpot NTRK, will be launched in August.

United Kingdom-based MC Diagnostics offers automated multiplex molecular tests and image analysis and interpretation software. The firm also offers HLA typing and blood group diagnostics on its ALDAS platform.

The ALDAS system has an eight-well strip array that allows up to 96 samples to be run at a time, with a turnaround time of three hours, ACT said.

Taipei-based ACT Genomics specializes in next-generation sequencing-based tests and oncology molecular diagnostics. The firm provides cancer treatment planning, immunotherapy evaluation, cancer relapse and drug resistance monitoring, and cancer risk assessment.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.